Trial Profile
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF MDV3100 IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Apr 2018 Status changed from active, no longer recruiting to completed.
- 10 Apr 2018 Status changed from active, no longer recruiting to completed.
- 07 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.